Dopamine Agonists Interactions

Do not use esmolol to control tachycardia in patients receiving dopamine due to risk of reducing cardiac contractility in presence of high systemic vascular resistance.

Source: NLP:esmolol hydrochloride

Hyaluronidase should not be used to enhance the dispersion and absorption of dopamine.

Source: NLP:hyaluronidase

Pressor agent that may cause effects on blood pressure when used with atomoxetine; use with caution.

Source: NLP:atomoxetine

Pressor agent; possible effects on blood pressure when used with atomoxetine.

Source: NLP:atomoxetine hydrochloride

May result in increased heart rates, arrhythmias, and excessive blood pressure changes when used with entacapone.

Source: NLP:carbidopa, levodopa and entacapone

May interfere with Fluorodopa F18 imaging. Consider discontinuing 12 hours before administration if safely possible.

Source: NLP:fluorodopa f18

Haloperidol may antagonize the effects of dopamine agonists and other drugs intended to increase dopamine levels.

Source: NLP:haloperidol decanoate

May reduce TSH secretion transiently at doses ≥1 mcg/kg/min when levothyroxine is used.

Source: NLP:levothyroxine sodium

Olanzapine may antagonize dopamine agonists.

Source: NLP:olanzapine

Olanzapine and fluoxetine may antagonize dopamine agonist effects.

Source: NLP:olanzapine and fluoxetine

Paliperidone may antagonize the effects of dopamine agonists. Monitor and manage patient as clinically appropriate.

Source: NLP:paliperidone palmitate

Quetiapine may antagonize the effects of dopamine agonists.

Source: NLP:quetiapine fumarate er

Risperidone may antagonize the effects of dopamine agonists.

Source: NLP:risperidone

Ziprasidone may antagonize the effects of dopamine agonists.

Source: NLP:ziprasidone

Ziprasidone may antagonize the effects of dopamine agonists, potentially reducing their therapeutic efficacy.

Source: NLP:ziprasidone hcl

Ziprasidone may antagonize the effects of dopamine agonists.

Source: NLP:ziprasidone mesylate